BCBrainstorm Cell Therapeutics Inc. BCLI · OTC
$0.78 +0.78% (+$0.01)
- Market cap
- $8.50M
- Enterprise value
- $9.85M
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- -
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- 60.1%
- Gross margin
- -
- Net margin
- -
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 0.24
- Free float
- 70.5%
About the company
Brainstorm Cell Therapeutics Inc. (BCLI) is a biotechnology company focused on researching and developing therapies for neurological disorders. The company specializes in utilizing its proprietary technologies and methods for treating and improving the quality of life for patients suffering from neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS). Brainstorm Cell Therapeutics is developing innovative cell-based therapeutic approaches that offer hope for improving the health of those grappling with these serious diseases. Investors interested in the biotechnology sector and medical research may find the shares of Brainstorm Cell Therapeutics Inc. (BCLI) to be an intriguing investment opportunity.
Sector
Healthcare
Industry
Biotechnology
CEO
Chaim Lebovits
Employees
19
Headquarters
New York City
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number